ARANELLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARANELLE (ARANELLE).
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation, with some involvement of CYP3A4. |
| Excretion | Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10% |
| Half-life | Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing |
| Protein binding | 97-98% bound to albumin and sex hormone-binding globulin (SHBG) |
| Volume of Distribution | 1.3-1.5 L/kg; moderate distribution into tissues including reproductive organs and liver |
| Bioavailability | Oral: approximately 85% (extensive first-pass metabolism; absolute bioavailability 85% based on IV reference) |
| Onset of Action | Oral: within 1-2 hours; peak effect 4-6 hours |
| Duration of Action | ~24 hours; therapeutic efficacy maintained throughout dosing interval |
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution. |
| Liver impairment | Contraindicated in patients with hepatic adenomas or active liver disease. Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to altered hormone metabolism. |
| Pediatric use | Safety and efficacy not established in pediatric patients before menarche. For post-menarchal adolescents, use same dosing as adults. |
| Geriatric use | Not indicated for use in postmenopausal women. No specific geriatric dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARANELLE (ARANELLE).
| Breastfeeding | Not recommended during breastfeeding. Small amounts of ethinyl estradiol and desogestrel are excreted in breast milk, but the M/P ratio is not well established. May decrease milk production and composition. |
| Teratogenic Risk | Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects, particularly during first trimester. Use in second and third trimesters may cause fetal feminization (in males) and virilization (in females). |
| Fetal Monitoring |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives; risk increases with age and smoking intensity, especially in women over 35. Women should not smoke while using ARANELLE.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","History of deep vein thrombosis or pulmonary embolism","Cerebrovascular or coronary artery disease","Current or history of breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Pregnancy","Liver tumors or active liver disease","Hypersensitivity to any component"]
| Precautions | ["Thrombotic disorders (e.g., venous thromboembolism, stroke, MI)","Cigarette smoking","Hypertension","Liver disease","Gallbladder disease","Glucose intolerance","Depression","Retinal thrombosis","Hereditary angioedema","Chloasma"] |
| Food/Dietary | No significant food interactions. Grapefruit juice has minimal effect on ethinyl estradiol pharmacokinetics; no restriction necessary. Avoid excessive alcohol consumption as it may increase liver strain. |
Loading safety data…
| Monitor for signs of thromboembolism, hypertension, hepatotoxicity, and glucose intolerance. In pregnancy or suspected pregnancy, perform pregnancy test and discontinue immediately. |
| Fertility Effects | Reversible suppression of ovulation; normal fertility returns after discontinuation. No known permanent adverse effects on fertility. |
| Clinical Pearls | ARANELLE (ethinyl estradiol and drospirenone) is a combined oral contraceptive with an anti-mineralocorticoid effect due to drospirenone. Monitor potassium levels in patients with renal impairment or on medications that increase potassium. The 24/4 regimen with 30 mcg ethinyl estradiol and 3 mg drospirenone provides excellent cycle control. Consider in patients with acne or mild hirsutism due to drospirenone's anti-androgenic properties. Contraindicated in patients with migraines with aura, history of thromboembolic events, or liver disease. |
| Patient Advice | Take one tablet daily at the same time for 24 days of active pills followed by 4 placebo days. · Use backup contraception (e.g., condoms) for the first 7 days if starting for the first time. · Report any signs of blood clots (leg pain, chest pain, sudden shortness of breath, severe headache, vision changes) immediately. · Avoid smoking due to increased risk of cardiovascular side effects. · Inform your healthcare provider of all medications, especially those affecting potassium (e.g., ACE inhibitors, NSAIDs, potassium supplements). · If you miss a dose, follow the package instructions; if you miss more than one pill, use backup contraception. |